Global Argininemia Drugs- Market

Argininemia Drugs- Comprehensive Study by Medications (Protein Intake Limited, Sodium Benzoate, Sodium Phenylbutyrate, Carglumic Acid, Others), Diagnosis (Plasma Ammonia Concentration, Urinary Orotic Acid Concentration, Red Blood Cell Arginase Enzyme Activity), Symptoms (Feeding Problems, Vomiting, Poor Growth, Seizures, Spasticity (stiff muscles with increased reflexes), Others) Players and Region - Global Market Outlook to 2028

Argininemia Drugs- Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Argininemia Drugs-
Argininemia (ARG) is a situation that motives hazardous quantities of arginine and ammonia to construct up in the body. It is viewed an amino acid circumstance due to the fact humans affected with ARG are unable to spoil down an amino acid, a small molecule that makes up proteins, recognized as arginine. Argininemia is an autosomal recessive disease inflicting hyper ammonemia secondary to arginine accumulation.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that Switzerland Players will contribute the maximum growth to Global Argininemia Drugs- market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Helsinn Healthcare (Switzerland), Novartis Pharmaceuticals (Switzerland), Medicis Pharmaceutical (United States) and Amgen Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Argininemia Drugs- market by and Region.



On the basis of geography, the market of Argininemia Drugs- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Medications, the sub-segment i.e. Protein Intake Limited will boost the Argininemia Drugs- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Plasma Ammonia Concentration will boost the Argininemia Drugs- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Feeding Problems will boost the Argininemia Drugs- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Use of Argininemia Drugs for Treatment

Market Growth Drivers:
Increasing Prevalence of Amino Acid Metabolism Disorder

Challenges:
Stringent Government Regulatory Requirement for the Approval of Drugs

Restraints:
Side Effect of the Argininemia Drugs

Opportunities:
Rising R&D Activities

Market Leaders and their expansionary development strategies
In December 2022, Amgen Inc. acquired Horizon Therapeutics for approximately USD 27.8 billion. This is year’s biggest biopharma acquisition deal to date. This acquisition helped company to expand its presence in argininemia drugs market
In 2021, Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, announced that the European Medicines Agency (EMA) accepted for review the Company’s Marketing Authorization Application (MAA) for infigratinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.


Key Target Audience
Manufacturers of Drugs, Suppliers, Distributors and Retailers Drugs, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Medications
  • Protein Intake Limited
  • Sodium Benzoate
  • Sodium Phenylbutyrate
  • Carglumic Acid
  • Others

By Diagnosis
  • Plasma Ammonia Concentration
  • Urinary Orotic Acid Concentration
  • Red Blood Cell Arginase Enzyme Activity

By Symptoms
  • Feeding Problems
  • Vomiting
  • Poor Growth
  • Seizures
  • Spasticity (stiff muscles with increased reflexes)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Amino Acid Metabolism Disorder
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulatory Requirement for the Approval of Drugs
    • 3.4. Market Trends
      • 3.4.1. Growing Use of Argininemia Drugs for Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Argininemia Drugs-, by Medications, Diagnosis, Symptoms and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Argininemia Drugs- (Value)
      • 5.2.1. Global Argininemia Drugs- by: Medications (Value)
        • 5.2.1.1. Protein Intake Limited
        • 5.2.1.2. Sodium Benzoate
        • 5.2.1.3. Sodium Phenylbutyrate
        • 5.2.1.4. Carglumic Acid
        • 5.2.1.5. Others
      • 5.2.2. Global Argininemia Drugs- by: Diagnosis (Value)
        • 5.2.2.1. Plasma Ammonia Concentration
        • 5.2.2.2. Urinary Orotic Acid Concentration
        • 5.2.2.3. Red Blood Cell Arginase Enzyme Activity
      • 5.2.3. Global Argininemia Drugs- by: Symptoms (Value)
        • 5.2.3.1. Feeding Problems
        • 5.2.3.2. Vomiting
        • 5.2.3.3. Poor Growth
        • 5.2.3.4. Seizures
        • 5.2.3.5. Spasticity (stiff muscles with increased reflexes)
        • 5.2.3.6. Others
      • 5.2.4. Global Argininemia Drugs- Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Argininemia Drugs- (Volume)
      • 5.3.1. Global Argininemia Drugs- by: Medications (Volume)
        • 5.3.1.1. Protein Intake Limited
        • 5.3.1.2. Sodium Benzoate
        • 5.3.1.3. Sodium Phenylbutyrate
        • 5.3.1.4. Carglumic Acid
        • 5.3.1.5. Others
      • 5.3.2. Global Argininemia Drugs- by: Diagnosis (Volume)
        • 5.3.2.1. Plasma Ammonia Concentration
        • 5.3.2.2. Urinary Orotic Acid Concentration
        • 5.3.2.3. Red Blood Cell Arginase Enzyme Activity
      • 5.3.3. Global Argininemia Drugs- by: Symptoms (Volume)
        • 5.3.3.1. Feeding Problems
        • 5.3.3.2. Vomiting
        • 5.3.3.3. Poor Growth
        • 5.3.3.4. Seizures
        • 5.3.3.5. Spasticity (stiff muscles with increased reflexes)
        • 5.3.3.6. Others
      • 5.3.4. Global Argininemia Drugs- Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Australia
          • 5.3.4.2.6. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Argininemia Drugs- (Price)
  • 6. Argininemia Drugs-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Helsinn Healthcare (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis Pharmaceuticals (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Medicis Pharmaceutical (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Argininemia Drugs- Sale, by Medications, Diagnosis, Symptoms and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Argininemia Drugs- (Value)
      • 7.2.1. Global Argininemia Drugs- by: Medications (Value)
        • 7.2.1.1. Protein Intake Limited
        • 7.2.1.2. Sodium Benzoate
        • 7.2.1.3. Sodium Phenylbutyrate
        • 7.2.1.4. Carglumic Acid
        • 7.2.1.5. Others
      • 7.2.2. Global Argininemia Drugs- by: Diagnosis (Value)
        • 7.2.2.1. Plasma Ammonia Concentration
        • 7.2.2.2. Urinary Orotic Acid Concentration
        • 7.2.2.3. Red Blood Cell Arginase Enzyme Activity
      • 7.2.3. Global Argininemia Drugs- by: Symptoms (Value)
        • 7.2.3.1. Feeding Problems
        • 7.2.3.2. Vomiting
        • 7.2.3.3. Poor Growth
        • 7.2.3.4. Seizures
        • 7.2.3.5. Spasticity (stiff muscles with increased reflexes)
        • 7.2.3.6. Others
      • 7.2.4. Global Argininemia Drugs- Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Argininemia Drugs- (Volume)
      • 7.3.1. Global Argininemia Drugs- by: Medications (Volume)
        • 7.3.1.1. Protein Intake Limited
        • 7.3.1.2. Sodium Benzoate
        • 7.3.1.3. Sodium Phenylbutyrate
        • 7.3.1.4. Carglumic Acid
        • 7.3.1.5. Others
      • 7.3.2. Global Argininemia Drugs- by: Diagnosis (Volume)
        • 7.3.2.1. Plasma Ammonia Concentration
        • 7.3.2.2. Urinary Orotic Acid Concentration
        • 7.3.2.3. Red Blood Cell Arginase Enzyme Activity
      • 7.3.3. Global Argininemia Drugs- by: Symptoms (Volume)
        • 7.3.3.1. Feeding Problems
        • 7.3.3.2. Vomiting
        • 7.3.3.3. Poor Growth
        • 7.3.3.4. Seizures
        • 7.3.3.5. Spasticity (stiff muscles with increased reflexes)
        • 7.3.3.6. Others
      • 7.3.4. Global Argininemia Drugs- Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Australia
          • 7.3.4.2.6. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Argininemia Drugs- (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Argininemia Drugs-: by Medications(USD Million)
  • Table 2. Argininemia Drugs- Protein Intake Limited , by Region USD Million (2017-2022)
  • Table 3. Argininemia Drugs- Sodium Benzoate , by Region USD Million (2017-2022)
  • Table 4. Argininemia Drugs- Sodium Phenylbutyrate , by Region USD Million (2017-2022)
  • Table 5. Argininemia Drugs- Carglumic Acid , by Region USD Million (2017-2022)
  • Table 6. Argininemia Drugs- Others , by Region USD Million (2017-2022)
  • Table 7. Argininemia Drugs-: by Diagnosis(USD Million)
  • Table 8. Argininemia Drugs- Plasma Ammonia Concentration , by Region USD Million (2017-2022)
  • Table 9. Argininemia Drugs- Urinary Orotic Acid Concentration , by Region USD Million (2017-2022)
  • Table 10. Argininemia Drugs- Red Blood Cell Arginase Enzyme Activity , by Region USD Million (2017-2022)
  • Table 11. Argininemia Drugs-: by Symptoms(USD Million)
  • Table 12. Argininemia Drugs- Feeding Problems , by Region USD Million (2017-2022)
  • Table 13. Argininemia Drugs- Vomiting , by Region USD Million (2017-2022)
  • Table 14. Argininemia Drugs- Poor Growth , by Region USD Million (2017-2022)
  • Table 15. Argininemia Drugs- Seizures , by Region USD Million (2017-2022)
  • Table 16. Argininemia Drugs- Spasticity (stiff muscles with increased reflexes) , by Region USD Million (2017-2022)
  • Table 17. Argininemia Drugs- Others , by Region USD Million (2017-2022)
  • Table 18. South America Argininemia Drugs-, by Country USD Million (2017-2022)
  • Table 19. South America Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 20. South America Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 21. South America Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 22. Brazil Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 23. Brazil Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 24. Brazil Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 25. Argentina Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 26. Argentina Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 27. Argentina Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 28. Rest of South America Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 29. Rest of South America Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 30. Rest of South America Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 31. Asia Pacific Argininemia Drugs-, by Country USD Million (2017-2022)
  • Table 32. Asia Pacific Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 33. Asia Pacific Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 34. Asia Pacific Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 35. China Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 36. China Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 37. China Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 38. Japan Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 39. Japan Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 40. Japan Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 41. India Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 42. India Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 43. India Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 44. South Korea Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 45. South Korea Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 46. South Korea Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 47. Australia Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 48. Australia Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 49. Australia Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 53. Europe Argininemia Drugs-, by Country USD Million (2017-2022)
  • Table 54. Europe Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 55. Europe Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 56. Europe Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 57. Germany Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 58. Germany Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 59. Germany Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 60. France Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 61. France Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 62. France Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 63. Italy Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 64. Italy Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 65. Italy Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 66. United Kingdom Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 67. United Kingdom Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 68. United Kingdom Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 69. Netherlands Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 70. Netherlands Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 71. Netherlands Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 72. Rest of Europe Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 73. Rest of Europe Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 74. Rest of Europe Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 75. MEA Argininemia Drugs-, by Country USD Million (2017-2022)
  • Table 76. MEA Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 77. MEA Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 78. MEA Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 79. Middle East Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 80. Middle East Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 81. Middle East Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 82. Africa Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 83. Africa Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 84. Africa Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 85. North America Argininemia Drugs-, by Country USD Million (2017-2022)
  • Table 86. North America Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 87. North America Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 88. North America Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 89. United States Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 90. United States Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 91. United States Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 92. Canada Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 93. Canada Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 94. Canada Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 95. Mexico Argininemia Drugs-, by Medications USD Million (2017-2022)
  • Table 96. Mexico Argininemia Drugs-, by Diagnosis USD Million (2017-2022)
  • Table 97. Mexico Argininemia Drugs-, by Symptoms USD Million (2017-2022)
  • Table 98. Argininemia Drugs- Sales: by Medications(K Units)
  • Table 99. Argininemia Drugs- Sales Protein Intake Limited , by Region K Units (2017-2022)
  • Table 100. Argininemia Drugs- Sales Sodium Benzoate , by Region K Units (2017-2022)
  • Table 101. Argininemia Drugs- Sales Sodium Phenylbutyrate , by Region K Units (2017-2022)
  • Table 102. Argininemia Drugs- Sales Carglumic Acid , by Region K Units (2017-2022)
  • Table 103. Argininemia Drugs- Sales Others , by Region K Units (2017-2022)
  • Table 104. Argininemia Drugs- Sales: by Diagnosis(K Units)
  • Table 105. Argininemia Drugs- Sales Plasma Ammonia Concentration , by Region K Units (2017-2022)
  • Table 106. Argininemia Drugs- Sales Urinary Orotic Acid Concentration , by Region K Units (2017-2022)
  • Table 107. Argininemia Drugs- Sales Red Blood Cell Arginase Enzyme Activity , by Region K Units (2017-2022)
  • Table 108. Argininemia Drugs- Sales: by Symptoms(K Units)
  • Table 109. Argininemia Drugs- Sales Feeding Problems , by Region K Units (2017-2022)
  • Table 110. Argininemia Drugs- Sales Vomiting , by Region K Units (2017-2022)
  • Table 111. Argininemia Drugs- Sales Poor Growth , by Region K Units (2017-2022)
  • Table 112. Argininemia Drugs- Sales Seizures , by Region K Units (2017-2022)
  • Table 113. Argininemia Drugs- Sales Spasticity (stiff muscles with increased reflexes) , by Region K Units (2017-2022)
  • Table 114. Argininemia Drugs- Sales Others , by Region K Units (2017-2022)
  • Table 115. South America Argininemia Drugs- Sales, by Country K Units (2017-2022)
  • Table 116. South America Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 117. South America Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 118. South America Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 119. Brazil Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 120. Brazil Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 121. Brazil Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 122. Argentina Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 123. Argentina Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 124. Argentina Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 125. Rest of South America Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 126. Rest of South America Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 127. Rest of South America Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 128. Asia Pacific Argininemia Drugs- Sales, by Country K Units (2017-2022)
  • Table 129. Asia Pacific Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 130. Asia Pacific Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 131. Asia Pacific Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 132. China Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 133. China Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 134. China Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 135. Japan Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 136. Japan Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 137. Japan Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 138. India Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 139. India Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 140. India Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 141. South Korea Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 142. South Korea Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 143. South Korea Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 144. Australia Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 145. Australia Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 146. Australia Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 147. Rest of Asia-Pacific Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 148. Rest of Asia-Pacific Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 149. Rest of Asia-Pacific Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 150. Europe Argininemia Drugs- Sales, by Country K Units (2017-2022)
  • Table 151. Europe Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 152. Europe Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 153. Europe Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 154. Germany Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 155. Germany Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 156. Germany Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 157. France Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 158. France Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 159. France Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 160. Italy Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 161. Italy Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 162. Italy Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 163. United Kingdom Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 164. United Kingdom Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 165. United Kingdom Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 166. Netherlands Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 167. Netherlands Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 168. Netherlands Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 169. Rest of Europe Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 170. Rest of Europe Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 171. Rest of Europe Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 172. MEA Argininemia Drugs- Sales, by Country K Units (2017-2022)
  • Table 173. MEA Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 174. MEA Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 175. MEA Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 176. Middle East Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 177. Middle East Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 178. Middle East Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 179. Africa Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 180. Africa Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 181. Africa Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 182. North America Argininemia Drugs- Sales, by Country K Units (2017-2022)
  • Table 183. North America Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 184. North America Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 185. North America Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 186. United States Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 187. United States Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 188. United States Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 189. Canada Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 190. Canada Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 191. Canada Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 192. Mexico Argininemia Drugs- Sales, by Medications K Units (2017-2022)
  • Table 193. Mexico Argininemia Drugs- Sales, by Diagnosis K Units (2017-2022)
  • Table 194. Mexico Argininemia Drugs- Sales, by Symptoms K Units (2017-2022)
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Argininemia Drugs-: by Medications(USD Million)
  • Table 200. Argininemia Drugs- Protein Intake Limited , by Region USD Million (2023-2028)
  • Table 201. Argininemia Drugs- Sodium Benzoate , by Region USD Million (2023-2028)
  • Table 202. Argininemia Drugs- Sodium Phenylbutyrate , by Region USD Million (2023-2028)
  • Table 203. Argininemia Drugs- Carglumic Acid , by Region USD Million (2023-2028)
  • Table 204. Argininemia Drugs- Others , by Region USD Million (2023-2028)
  • Table 205. Argininemia Drugs-: by Diagnosis(USD Million)
  • Table 206. Argininemia Drugs- Plasma Ammonia Concentration , by Region USD Million (2023-2028)
  • Table 207. Argininemia Drugs- Urinary Orotic Acid Concentration , by Region USD Million (2023-2028)
  • Table 208. Argininemia Drugs- Red Blood Cell Arginase Enzyme Activity , by Region USD Million (2023-2028)
  • Table 209. Argininemia Drugs-: by Symptoms(USD Million)
  • Table 210. Argininemia Drugs- Feeding Problems , by Region USD Million (2023-2028)
  • Table 211. Argininemia Drugs- Vomiting , by Region USD Million (2023-2028)
  • Table 212. Argininemia Drugs- Poor Growth , by Region USD Million (2023-2028)
  • Table 213. Argininemia Drugs- Seizures , by Region USD Million (2023-2028)
  • Table 214. Argininemia Drugs- Spasticity (stiff muscles with increased reflexes) , by Region USD Million (2023-2028)
  • Table 215. Argininemia Drugs- Others , by Region USD Million (2023-2028)
  • Table 216. South America Argininemia Drugs-, by Country USD Million (2023-2028)
  • Table 217. South America Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 218. South America Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 219. South America Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 220. Brazil Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 221. Brazil Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 222. Brazil Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 223. Argentina Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 224. Argentina Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 225. Argentina Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 226. Rest of South America Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 227. Rest of South America Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 228. Rest of South America Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 229. Asia Pacific Argininemia Drugs-, by Country USD Million (2023-2028)
  • Table 230. Asia Pacific Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 231. Asia Pacific Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 232. Asia Pacific Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 233. China Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 234. China Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 235. China Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 236. Japan Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 237. Japan Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 238. Japan Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 239. India Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 240. India Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 241. India Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 242. South Korea Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 243. South Korea Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 244. South Korea Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 245. Australia Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 246. Australia Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 247. Australia Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 248. Rest of Asia-Pacific Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 249. Rest of Asia-Pacific Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 250. Rest of Asia-Pacific Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 251. Europe Argininemia Drugs-, by Country USD Million (2023-2028)
  • Table 252. Europe Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 253. Europe Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 254. Europe Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 255. Germany Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 256. Germany Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 257. Germany Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 258. France Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 259. France Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 260. France Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 261. Italy Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 262. Italy Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 263. Italy Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 264. United Kingdom Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 265. United Kingdom Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 266. United Kingdom Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 267. Netherlands Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 268. Netherlands Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 269. Netherlands Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 270. Rest of Europe Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 271. Rest of Europe Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 272. Rest of Europe Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 273. MEA Argininemia Drugs-, by Country USD Million (2023-2028)
  • Table 274. MEA Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 275. MEA Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 276. MEA Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 277. Middle East Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 278. Middle East Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 279. Middle East Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 280. Africa Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 281. Africa Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 282. Africa Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 283. North America Argininemia Drugs-, by Country USD Million (2023-2028)
  • Table 284. North America Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 285. North America Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 286. North America Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 287. United States Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 288. United States Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 289. United States Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 290. Canada Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 291. Canada Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 292. Canada Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 293. Mexico Argininemia Drugs-, by Medications USD Million (2023-2028)
  • Table 294. Mexico Argininemia Drugs-, by Diagnosis USD Million (2023-2028)
  • Table 295. Mexico Argininemia Drugs-, by Symptoms USD Million (2023-2028)
  • Table 296. Argininemia Drugs- Sales: by Medications(K Units)
  • Table 297. Argininemia Drugs- Sales Protein Intake Limited , by Region K Units (2023-2028)
  • Table 298. Argininemia Drugs- Sales Sodium Benzoate , by Region K Units (2023-2028)
  • Table 299. Argininemia Drugs- Sales Sodium Phenylbutyrate , by Region K Units (2023-2028)
  • Table 300. Argininemia Drugs- Sales Carglumic Acid , by Region K Units (2023-2028)
  • Table 301. Argininemia Drugs- Sales Others , by Region K Units (2023-2028)
  • Table 302. Argininemia Drugs- Sales: by Diagnosis(K Units)
  • Table 303. Argininemia Drugs- Sales Plasma Ammonia Concentration , by Region K Units (2023-2028)
  • Table 304. Argininemia Drugs- Sales Urinary Orotic Acid Concentration , by Region K Units (2023-2028)
  • Table 305. Argininemia Drugs- Sales Red Blood Cell Arginase Enzyme Activity , by Region K Units (2023-2028)
  • Table 306. Argininemia Drugs- Sales: by Symptoms(K Units)
  • Table 307. Argininemia Drugs- Sales Feeding Problems , by Region K Units (2023-2028)
  • Table 308. Argininemia Drugs- Sales Vomiting , by Region K Units (2023-2028)
  • Table 309. Argininemia Drugs- Sales Poor Growth , by Region K Units (2023-2028)
  • Table 310. Argininemia Drugs- Sales Seizures , by Region K Units (2023-2028)
  • Table 311. Argininemia Drugs- Sales Spasticity (stiff muscles with increased reflexes) , by Region K Units (2023-2028)
  • Table 312. Argininemia Drugs- Sales Others , by Region K Units (2023-2028)
  • Table 313. South America Argininemia Drugs- Sales, by Country K Units (2023-2028)
  • Table 314. South America Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 315. South America Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 316. South America Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 317. Brazil Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 318. Brazil Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 319. Brazil Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 320. Argentina Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 321. Argentina Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 322. Argentina Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 323. Rest of South America Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 324. Rest of South America Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 325. Rest of South America Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 326. Asia Pacific Argininemia Drugs- Sales, by Country K Units (2023-2028)
  • Table 327. Asia Pacific Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 328. Asia Pacific Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 329. Asia Pacific Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 330. China Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 331. China Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 332. China Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 333. Japan Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 334. Japan Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 335. Japan Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 336. India Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 337. India Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 338. India Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 339. South Korea Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 340. South Korea Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 341. South Korea Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 342. Australia Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 343. Australia Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 344. Australia Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 345. Rest of Asia-Pacific Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 346. Rest of Asia-Pacific Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 347. Rest of Asia-Pacific Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 348. Europe Argininemia Drugs- Sales, by Country K Units (2023-2028)
  • Table 349. Europe Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 350. Europe Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 351. Europe Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 352. Germany Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 353. Germany Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 354. Germany Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 355. France Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 356. France Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 357. France Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 358. Italy Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 359. Italy Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 360. Italy Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 361. United Kingdom Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 362. United Kingdom Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 363. United Kingdom Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 364. Netherlands Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 365. Netherlands Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 366. Netherlands Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 367. Rest of Europe Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 368. Rest of Europe Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 369. Rest of Europe Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 370. MEA Argininemia Drugs- Sales, by Country K Units (2023-2028)
  • Table 371. MEA Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 372. MEA Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 373. MEA Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 374. Middle East Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 375. Middle East Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 376. Middle East Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 377. Africa Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 378. Africa Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 379. Africa Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 380. North America Argininemia Drugs- Sales, by Country K Units (2023-2028)
  • Table 381. North America Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 382. North America Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 383. North America Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 384. United States Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 385. United States Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 386. United States Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 387. Canada Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 388. Canada Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 389. Canada Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 390. Mexico Argininemia Drugs- Sales, by Medications K Units (2023-2028)
  • Table 391. Mexico Argininemia Drugs- Sales, by Diagnosis K Units (2023-2028)
  • Table 392. Mexico Argininemia Drugs- Sales, by Symptoms K Units (2023-2028)
  • Table 393. Research Programs/Design for This Report
  • Table 394. Key Data Information from Secondary Sources
  • Table 395. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Argininemia Drugs-: by Medications USD Million (2017-2022)
  • Figure 5. Global Argininemia Drugs-: by Diagnosis USD Million (2017-2022)
  • Figure 6. Global Argininemia Drugs-: by Symptoms USD Million (2017-2022)
  • Figure 7. South America Argininemia Drugs- Share (%), by Country
  • Figure 8. Asia Pacific Argininemia Drugs- Share (%), by Country
  • Figure 9. Europe Argininemia Drugs- Share (%), by Country
  • Figure 10. MEA Argininemia Drugs- Share (%), by Country
  • Figure 11. North America Argininemia Drugs- Share (%), by Country
  • Figure 12. Global Argininemia Drugs-: by Medications K Units (2017-2022)
  • Figure 13. Global Argininemia Drugs-: by Diagnosis K Units (2017-2022)
  • Figure 14. Global Argininemia Drugs-: by Symptoms K Units (2017-2022)
  • Figure 15. South America Argininemia Drugs- Share (%), by Country
  • Figure 16. Asia Pacific Argininemia Drugs- Share (%), by Country
  • Figure 17. Europe Argininemia Drugs- Share (%), by Country
  • Figure 18. MEA Argininemia Drugs- Share (%), by Country
  • Figure 19. North America Argininemia Drugs- Share (%), by Country
  • Figure 20. Global Argininemia Drugs- share by Players 2022 (%)
  • Figure 21. BCG Matrix for key Companies
  • Figure 22. Helsinn Healthcare (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Helsinn Healthcare (Switzerland) Revenue: by Geography 2022
  • Figure 24. Novartis Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis Pharmaceuticals (Switzerland) Revenue: by Geography 2022
  • Figure 26. Medicis Pharmaceutical (United States) Revenue, Net Income and Gross profit
  • Figure 27. Medicis Pharmaceutical (United States) Revenue: by Geography 2022
  • Figure 28. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Amgen Inc. (United States) Revenue: by Geography 2022
  • Figure 30. Global Argininemia Drugs-: by Medications USD Million (2023-2028)
  • Figure 31. Global Argininemia Drugs-: by Diagnosis USD Million (2023-2028)
  • Figure 32. Global Argininemia Drugs-: by Symptoms USD Million (2023-2028)
  • Figure 33. South America Argininemia Drugs- Share (%), by Country
  • Figure 34. Asia Pacific Argininemia Drugs- Share (%), by Country
  • Figure 35. Europe Argininemia Drugs- Share (%), by Country
  • Figure 36. MEA Argininemia Drugs- Share (%), by Country
  • Figure 37. North America Argininemia Drugs- Share (%), by Country
  • Figure 38. Global Argininemia Drugs-: by Medications K Units (2023-2028)
  • Figure 39. Global Argininemia Drugs-: by Diagnosis K Units (2023-2028)
  • Figure 40. Global Argininemia Drugs-: by Symptoms K Units (2023-2028)
  • Figure 41. South America Argininemia Drugs- Share (%), by Country
  • Figure 42. Asia Pacific Argininemia Drugs- Share (%), by Country
  • Figure 43. Europe Argininemia Drugs- Share (%), by Country
  • Figure 44. MEA Argininemia Drugs- Share (%), by Country
  • Figure 45. North America Argininemia Drugs- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Helsinn Healthcare (Switzerland)
  • Novartis Pharmaceuticals (Switzerland)
  • Medicis Pharmaceutical (United States)
  • Amgen Inc. (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 241 Pages 95 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Argininemia Drugs- Market Quantitative research analysis
Global Argininemia Drugs- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Helsinn Healthcare (Switzerland), Novartis Pharmaceuticals (Switzerland), Medicis Pharmaceutical (United States) and Amgen Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Use of Argininemia Drugs for Treatment" is seen as one of major influencing trends for Argininemia Drugs- Market during projected period 2022-2028.
The Argininemia Drugs- market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Argininemia Drugs- Market Report?

Have a Query? Click Here

Other Related Reports

Perineural Therapy Comprehensive Study by Type (Internal Neurostimulation Devices {Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electrical Stimulation, Spinal Cord Stimulation, Deep Bra...
$ 3800
Triptorelin Drug- Comprehensive Study by Application (Advanced prostate cancer, Endometriosis, Uterine fibroids, Precocious puberty), Doses Forms (3.75 mg Vial, 11.25 mg Vial, 22.5 mg Vial) Players a...
$ 3400
Quadriplegia Treatment Comprehensive Study by Administration (Oral, Intravenous, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores) Players and Region ...
$ 3400
Sleep Supplements Comprehensive Study by Prescription (Antidepressants, Benzodiazepines, Z-drugs (Ambien® and Lunesta®)), Form (Capsule, Liquid, Powder, Others), Distribution Channel (Hospital Pharm...
$ 3800
Cannabis Seeds Comprehensive Study by Type (Regular Seeds, Feminized Seeds, Autoflowering Seeds), Application (Personal Care Products, Pharmaceuticals), Category (Organic, Conventional), Species (Hyb...
$ 3800
Sleep Paralysis Treatment Comprehensive Study by Type (Isolated Sleep Paralysis, Recurrent Sleep Paralysis), Application (Hospitals, Long Term Care Centers, Others), Drug (Benzodiazepines, Nonbenzodi...
$ 3800